Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system

Bibliography

• Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36(11):1404-10
   PubMed Web of Science ®Google Scholar
• Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am 2000;84(6):1447-69
   PubMed Web of Science ®Google Scholar
• Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004;49(2):S73-8
   PubMed Web of Science ®Google Scholar
• Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-S157
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis Off Publ Infect Dis Soc Am 1999;28(2):352-64
   PubMed Web of Science ®Google Scholar
• Commissioner O of the. 2008. FDA requests boxed warnings on fluoroquinolone antimicrobial drugs. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919.htm [Last accessed 3 April 2015]
   Google Scholar
• Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125(12):1228e23-8
   Web of Science ®Google Scholar
• van der Linden PD, Sturkenboom MCJM, Herings R, et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003;163(15):1801
   PubMed Web of Science ®Google Scholar
• Tsai W-C, Yang Y-M. Fluoroquinolone-associated tendinopathy. Chang Gung Med J 2011;34(5):461-7
   PubMedGoogle Scholar
• Kaleagasioglu F, Olcay E. Fluoroquinolone-induced tendinopathy: etiology and preventive measures. Tohoku J Exp Med 2012;226(4):251-8
   PubMed Web of Science ®Google Scholar
• Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002;25(6):393-7
   PubMed Web of Science ®Google Scholar
• Cook JL, Khan KM, Purdam C. Achilles tendinopathy. Man Ther 2002;7(3):121-30
   PubMed Web of Science ®Google Scholar
• Research C for DE and FDA adverse event reporting system (FAERS). Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm [Last accessed 3 April 2015]
   Google Scholar
• FDA Adverse Event Reporting System (FAERS) Statistics 2013
   Google Scholar
• MedWatch: The FDA Safety Information and Adverse Event Reporting System. 2013
   Google Scholar
• Research C for DE and. FDA adverse events reporting system (FAERS) - potential signals of serious risks/new safety information identified from the FDA adverse event reporting system (FAERS). Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082196.htm [Last accessed 3 April 2015]
   Google Scholar
• Freedom of Information Act (FOIA). 5 US Congress. 552 (1994 & Supp. II 1996). (Journal Article)
   Google Scholar
• Research C for DE and. FDA adverse events reporting system (FAERS) - FAERS domestic and foreign reports by year. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070441.htm [Last accessed 3 August 2015]
   Google Scholar
• Hauben M, Zhou X. Quantitative methods in pharmacovigilance. Drug Saf 2003;26(3):159-86
   PubMed Web of Science ®Google Scholar
• DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999;53(3):177-90
   Web of Science ®Google Scholar
• DuMouchel W, Smith ET, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004;26(7):1092-104
   PubMed Web of Science ®Google Scholar
• Edwards BJ, Bunta AD, Lane J, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA adverse event reporting system (FAERS) and international safety effortsa systematic review from the research on adverse drug events and reports (RADAR) project. J Bone Jt Surg 2013;95(4):297-307
   PubMed Web of Science ®Google Scholar
• Bond C, Hannaford P. Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Saf 2003;26(15):1065-74
   PubMed Web of Science ®Google Scholar
• Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf 2006;15(11):784-92
   PubMed Web of Science ®Google Scholar
• Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007;63(5):499-503
   PubMed Web of Science ®Google Scholar
• MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. Antimicrobial Drug Prescribing for Pneumonia in Ambulatory Care. Emerg Infect Dis 2005;11(3):380-4
   PubMed Web of Science ®Google Scholar
• Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118(3):259-68
   PubMed Web of Science ®Google Scholar
• Van der Linden P, Sturkenboom M, Herings R, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324(7349):1306-7
   PubMed Web of Science ®Google Scholar
• Sendzik J, Shakibaei M, Schäfer-Korting M, et al. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents 2010;35(4):366-74
   PubMed Web of Science ®Google Scholar
• Garg V, Raisch DW, McKoy JM, et al. Impact of United States Food and Drug Administration’s boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Expert Opin Drug Saf 2013;12(3):299-307
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 2013;108(6):866-72
   PubMed Web of Science ®Google Scholar
• Taylor J, Pemberton MN. Yellow card scheme. Br Dent J 2013;215(2):59
   PubMed Web of Science ®Google Scholar
• Government of Canada HC. MedEffect Canada - Health Canada. 2011. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/index-eng.php [Last accessed 3 April 2015]
   Google Scholar
• Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBaseTM. Drug Saf 2012;35(12):1171-82
   PubMed Web of Science ®Google Scholar
• Moss PJ, Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax 2000;55(1):83-5
   PubMed Web of Science ®Google Scholar
• Furqan S, Paracha SAU. Frequency of streptococcus pneumonia and Haemophilus influenza in acute exacerbation of chronic obstructive airway disease and their sensitivity to levofloxacin. JPMA J Pak Med Assoc 2014;64(4):399-402
   PubMed Web of Science ®Google Scholar
• Butler MW, Griffin JF, Quinlan WR, McDonnell TJ. Quinolone-associated tendonitis: a potential problem in COPD? Ir J Med Sci 2001;170(3):198-9
   PubMed Web of Science ®Google Scholar
• Braun D, Petitpain N, Cosserat F, et al. Rupture of multiple tendons after levofloxacin therapy. Joint Bone Spine 2004;71(6):586-7
   PubMed Web of Science ®Google Scholar
• Werner NL, Hecker MT, Sethi AK, Donskey CJ. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 2011;11:187
   PubMed Web of Science ®Google Scholar
• Kim GK. The Risk of Fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? J Clin Aesthetic Dermatol 2010;3(4):49-54
   PubMedGoogle Scholar
• Corrao G, Zambon A, Bertù L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006;29(10):889-96
   PubMed Web of Science ®Google Scholar
• Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45(3):301-8
   PubMed Web of Science ®Google Scholar
• Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004;27(7):477-87
   PubMed Web of Science ®Google Scholar